Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 16/20 | 0.42 |
| ▸ | CTSK | P43235 | 16/20 | 0.42 |
| ▸ | CTSS | P25774 | 12/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 4/20 | 0.35 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.34 |
| ▸ | CTSV | O60911 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4319060 | 1.00 | CTSL (0.42) | CTSLCTSKCTSSTSHRGFER | |
| SCHEMBL4309331 | 1.00 | CTSL (0.42) | CTSLCTSKCTSSTSHRGFER | |
| SCHEMBL4312275 | 1.00 | CTSL (0.42) | CTSLCTSKCTSSTSHRGFER | |
| SCHEMBL4693518 | 0.86 | CTSK (0.41) | CTSLCTSKCTSSCTSBCTSV | |
| SCHEMBL5105298 | 0.85 | CTSK (0.34) | CTSLCTSKCTSSCTSBELOVL6 | |
| SCHEMBL4316610 | 0.84 | CTSK (0.55) | CTSLCTSKCTSSCTSBCTSV | |
| SCHEMBL4310542 | 0.84 | CTSK (0.55) | CTSLCTSKCTSSCTSBCTSV | |
| SCHEMBL5096633 | 0.84 | CTSK (0.55) | CTSLCTSKCTSSCTSBCTSV | |
| SCHEMBL4319067 | 0.84 | CTSK (0.40) | CTSLCTSKCTSSCTSBELOVL6 | |
| SCHEMBL4314724 | 0.84 | CTSK (0.40) | CTSLCTSKCTSSCTSBELOVL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194787-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | claimed |
| US-20040044201-A1 | Protease inhibitors | GLAXOSMITHKLINE LLC | 2004-03-04 | — | — | US | claimed |
| US-7563784-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-20060194787-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | disclosed |
| US-7071184-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| US-20040044201-A1 | Protease inhibitors | GLAXOSMITHKLINE LLC | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194787-A1 | Protease inhibitors | CTSK, CTSL, CTSZ | CTSL 2/4885CTSK 1/4885CTSS 4/4885 |
| US-20040044201-A1 | Protease inhibitors | CTSK, CTSE, CTSZ | CTSL 11/4885CTSK 1/4885CTSS 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.